Medical
-
Revelation Biosciences announced that the Australian Therapeutic Goods Administration has okayed a Phase 1 clinical study of the company’s REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), which Revelation is developing for the treatment of COVID‑19. According… Read more . . .
-
A consortium formed by Irish biotech OmniSpirant, nebulizer maker Aerogen, and the National University of Ireland Galway has received a €11.6 million grant from Ireland’s Disruptive Technologies Innovation Fund for development of OS002, an inhaled… Read more . . .
-
Researchers from the University of Texas at Austin and Chungnam National University have published in vitro and in vivo data demonstrating that a dry powder formulation of niclosamide that includes human lysozyme (hLYS) as a… Read more . . .
-
Ena Respiratory (formerly Innavac) said that its INNA-051 pegylated TLR2/6 agonist nasal spray reduced replication of the SARS-CoV-2 virus in a ferret model by up to 96% in a study conducted by researchers at Public… Read more . . .
-
TFF Pharmaceuticals is drawing attention to in vitro data published by researchers at the University of Texas Austin which found that thin film freezing “produces high potency remdesivir dry powder formulations for inhalation suitable to… Read more . . .
-
Neurelis has announced plans to conduct a clinical trial of Valtoco diazepam nasal spray in children with epilepsy aged 2-5 and said that the company intends to file an sNDA to expand the use of… Read more . . .
-
French biotech company Alaxia has announced a collaboration with the Department of Molecular Medicine (DMM) at the University of Padua for in vitro testing of its ALX-009 hypothiocyanite / lactoferrin inhalation solution against SARS-CoV-2 as… Read more . . .
-
Ampio Pharmaceuticals said that the FDA has cleared its IND for clinical trials of an inhaled formulation of its Ampion anti-inflammatory biologic in patients with COVID-19. The company had announced its plans to develop Ampion for… Read more . . .
-
TFF Pharmaceuticals has announced that it will advance its voriconazole inhalation powder into Phase 2 development for the treatment of invasive pulmonary aspergillosis following completion of a Phase 1 trial that demonstrated plasma levels that… Read more . . .
-
Starpharma has announced that testing of its SPL7013 astodrimer sodium intranasal formulation at the Scripps Research Institute demonstrated that the formulation inactivated nearly 100% of SARS-CoV-2 with low cellular toxicity. The company already markets several… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany